Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on German News Wire.
Press releases published on April 23, 2025
First Atlantic Nickel Intersects 0.23% Nickel and 0.31% Chromium Over 366 Meters in Third Drill Hole at RPM Zone, Confirming at Least 500-Meter Mineralized Width
GlobeNewswire
·
April 23, 2025
VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) -- First Atlantic Nickel Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P21) ("First Atlantic" or the "Company") is pleased to announce assay results from drill hole AN-24-04, the third drill hole at the …
Dr. Stephan Rietiker elected as new Chairman of the Board of MetrioPharm AG
GlobeNewswire
·
April 23, 2025
Dr. Rietiker has considerable experience in the life sciences industry, including leadership positions in global pharmaceutical and medical device companies, and has overseen multiple major company acquisitions. Zurich, April 23, 2025 – MetrioPharm AG, a …
Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers
GlobeNewswire
·
April 23, 2025
Ingelheim, Germany and Amsterdam, the Netherlands, 23 April 2025 – Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into a research collaboration and global …
Hi-View Resources Discovers Multiple Anomalous Structures from Airborne Tri-Axial Gradiometer Survey Results
GlobeNewswire
·
April 23, 2025
VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) -- HI-VIEW RESOURCES INC. (‘HI-VIEW' OR THE ‘COMPANY’) (CSE: HVW; OTCQB: HVWRF; FSE: B63) announces it has identified multiple linear anomalies related to faults and structures on its Lawyers …
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies
GlobeNewswire
·
April 23, 2025
VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE") Candidates, with Strong and Differentiated Clinical …